Novo Nordisk is betting on a new pipeline of obesity and diabetes drugs as Eli Lilly widens its lead in GLP-1s, including in the growing oral pill market and Medicare-covered obesity treatments.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0